NFE2L2 and breast neoplasm: In this regard, the initial studies identified NRF2 as a negative regulator of RON (Recepteur d’ origine nantais) gene expression, a tyrosine kinase receptor frequently overactivated in breast tumors and associated with tamoxifen resistance, as well as metastatic disease [34].